摘要
目的研究多巴丝肼联合盐酸司来吉兰治疗对帕金森病患者精神及运动状态的影响。方法回顾性选取2021年1月至2024年12月南通市第一人民医院收治的120例帕金森病患者,按照不同治疗方案将患者分为观察组(n=60)和对照组(n=60)。观察组给予多巴丝肼与盐酸司来吉兰联合治疗,对照组给予多巴丝肼治疗,两组治疗周期均为6个月。治疗前、治疗6个月后,采用帕金森病统一评分量表(UPDRS)评估患者的运动功能,采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评估患者的精神状态;治疗6个月后,采用Webster症状评分量表评估两组的临床疗效;并记录两组患者的不良反应发生情况。结果治疗6个月后,两组UPDRS评分均较治疗前降低,且观察组UPDRS评分为(19.21±3.36)分,低于对照组[(25.14±3.48)分],差异均有统计学意义(P<0.05)。治疗6个月后,两组患者的HAMD和HAMA评分均较治疗前降低,且观察组的HAMD和HAMA评分分别为(9.58±1.23)、(8.85±1.43)分,均低于对照组[(11.42±1.49)、(11.49±1.59)分],差异均有统计学意义(P<0.05)。观察组总有效率为85.00%,高于对照组(65.00%),差异有统计学意义(P<0.05)。两组总不良反应发生率比较(6.67%vs.8.33%),差异无统计学意义(P>0.05)。结论与单纯多巴丝肼治疗比较,多巴丝肼与盐酸司来吉兰的联合应用可有效改善帕金森病患者的运动功能和精神状态,提高治疗有效率,且具有较高的安全性,值得临床推广应用。
Objective To investigate the effects of dopa serazine combined with selegiline hydrochloride on mental and motor status in patients with Parkinson's disease.Methods A total of 120 patients with Parkinson's disease admitted to the First People's Hospital of Nantong from January 2021 to December 2024 were retrospectively selected,and the patients were divided into the observation group(n=60)and the control group(n=60)according to different treatment regimens.The observation group was treated with dopa serazine combined with selegiline hydrochloride,and the control group was treated with dopa serazine.The treatment period of the two groups was 6 months.The treatment period of the two groups was 6 months.Before treatment and 6 months after treatment,the unified Parkinson disease rating scale(UPDRS)was used to evaluate the motor function of the patients,and the Hamilton depression scale(HAMD)and Hamilton anxiety scale(HAMA)were used to evaluate the mental state of the patients.After 6 months of treatment,the clinical efficacy of the two groups was evaluated by Webster symptom score scale.The adverse reactions of the two groups were recorded.Results After 6 months of treatment,the UPDRS scores of the two groups were lower than those before treatment,and the UPDRS score of the observation group was(19.21±3.36)points,which was lower than that of the control group[(25.14±3.48)points],the differences were statistically significant(P<0.05).After 6 months of treatment,the HAMD and HAMA scores of the two groups were lower than those before treatment,and the HAMD and HAMA scores of the observation group were(9.58±1.23)and(8.85±1.43)points,respectively,which were lower than those of the control group[(11.42±1.49)and(11.49±1.59)points],the differences were statistically significant(P<0.05).The total effective rate of the observation group was 85.00%,which was higher than that of the control group(65.00%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of total adverse reactions between the two groups(6.67%vs.8.33%)(P>0.05).Conclusion These results collectively indicate that combining dopa serazine with selegiline hydrochloride provides superior clinical benefits while maintaining equivalent safety to monotherapy,enhance their self-care ability in daily life,and has high safety,which is suitable for widespread promotion in clinical practice.
作者
姚凯锋
朱向阳
王丽华
魏银丽
YAO Kaifeng;ZHU Xiangyang;WANG Lihua(Department of Neurosurgery,The First People's Hospital of Nantong,Nantong Jiangsu 226001,China;Department of Neurology,The First People's Hospital of Nantong,Nantong Jiangsu 226001,China)
出处
《临床和实验医学杂志》
2025年第22期2375-2378,共4页
Journal of Clinical and Experimental Medicine
基金
江苏省卫健委课题面上项目(编号:H210957)。
关键词
帕金森病
多巴丝肼
盐酸司来吉兰
运动功能
精神状态
Parkinson's disease
Dopa serazide
Selegiline hydrochloride
Motor function
Mental state
